EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of Sclerostin in Cardiovascular System

Ning Zhang, Luyao Wang, Xiaofei Li, Xin Yang iD, Xiaohui Tao iD, Hewen Jiang, Yuanyuan Yu, Jin Liu, Sifan Yu, Yuan Ma, Baoting Zhang, Ge Zhang iD

International Journal of Molecular Sciences · 09.05.2025 · 26 (10) · 4552

DOI: 10.3390/ijms26104552 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2025. Verfasst von Ning Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China. Hauptthemen laut MEDLINE: Adaptor Proteins, Signal Transducing, Cardiovascular Diseases, Cardiovascular System. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Hong Kong General Research Fund, Young Scientists Fund of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sclerostin, encoded by the SOST gene, is a novel bone anabolic target for bone diseases. Humanized anti-sclerostin antibody, romosozumab, was approved for treatment of postmenopausal osteoporosis by the US Food and Drug Administration (FDA), but with a black-box warning on cardiovascular risk. The clinical data regarding cardiovascular events from various pre-marketing and post-marketing studies of romosozumab were inconsistent. Overall, the cardiovascular risk of sclerostin inhibition could not be excluded. The restriction of romosozumab in patients with cardiovascular disease history would be necessary. Moreover, genome-wide association study (GWAS) analyses of SOST variants revealed inconsistent results of the association between SOST variations and cardiovascular diseases. Further research incorporating larger sample sizes and functional analyses are necessary. In analyses of serum/tissue sclerostin levels in patients with cardiovascular diseases, the results were controversial but indicated an association between sclerostin and the presence/severity/outcomes of cardiovascular diseases. Nonclinical studies in rodents indicated the inhibitory effect of sclerostin on inflammation, aortic aneurysm, atherosclerosis, and vascular calcification. Sclerostin loop3 participated in the inhibitory effect of sclerostin on bone formation, while the cardiovascular protective effect of sclerostin was independent of sclerostin loop3. Macrophagic sclerostin loop2–apolipoprotein E receptor 2 (ApoER2) interaction participated in the inhibitory effect of sclerostin on inflammation in vitro. Sclerostin in human aortic smooth muscle cells participated in the reduction in calcium deposition. The role of sclerostin in cardiovascular system deserves further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adaptor Proteins, Signal TransducingCardiovascular DiseasesCardiovascular SystemHumansAnimalsGenome-Wide Association StudyGenetic MarkersAntibodies, Monoclonal

Stichwörter der Autor:innen

cardiovascular systemclinical datamolecular understandingnonclinical datasclerostin

Substanzen

Adaptor Proteins, Signal TransducingSOST protein, humanromosozumabGenetic MarkersAntibodies, Monoclonal

Autor:innen und Institutionen

  • School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong 999077, China.
  • Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform for Aptamer-Based Translational Medicine and Drug Discovery (HKAP), Hong Kong 999077, China.
  • Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint Diseases (TMBJ), Hong Kong Baptist University, Hong Kong 999077, China.

ORCID-Profile: Xin Yang, Xiaohui Tao, Ge Zhang

Förderung

  • National Key R&D Program of China
  • Hong Kong General Research Fund
  • Young Scientists Fund of the National Natural Science Foundation of China
  • Hong Kong RGC Postdoctoral Fellowship Scheme
  • National Key R&D Program of China
  • CUHK Direct Grant
  • Theme-based Research Scheme
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Zhang, N., Wang, L., Li, X., Yang, X., Tao, X., Jiang, H., Yu, Y., Liu, J., Yu, S., Ma, Y., Zhang, B., & Zhang, G. (2025). Role of Sclerostin in Cardiovascular System. International Journal of Molecular Sciences, 26(10), 4552. https://doi.org/10.3390/ijms26104552

Vancouver

Zhang N, Wang L, Li X, Yang X, Tao X, Jiang H, et al. Role of Sclerostin in Cardiovascular System. International Journal of Molecular Sciences. 2025;26(10):4552. doi:10.3390/ijms26104552

BibTeX
@article{Zhang2025,
  author = {Zhang, Ning and Wang, Luyao and Li, Xiaofei and Yang, Xin and Tao, Xiaohui and Jiang, Hewen and Yu, Yuanyuan and Liu, Jin and Yu, Sifan and Ma, Yuan and Zhang, Baoting and Zhang, Ge},
  title = {Role of Sclerostin in Cardiovascular System},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {10},
  pages = {4552},
  doi = {10.3390/ijms26104552}
}
Kostenlos starten →